Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
“The pandemic has shone a bright light on the need for clinical trial participation as never before in history,” said
Greater Gift’s programs celebrate clinical trial participants by making donations on behalf of those individuals to reinforce the impact of their contribution on the advancement of clinical research. Celebrations of clinical trial participants have provided an additional benefit of 130,000 vaccines and meals to children in need through prior programs.
“AGTC is thrilled to partner with Greater Gift to honor clinical trial participants and their families for their contribution to the clinical research community,” said
Greater Gift partnered with 2020 On-site because of the organization’s commitment to the underserved through their relationship with the
“We are honored to be part of this partnership with AGTC and Greater Gift. Both companies align with our mission to make eye care more accessible and to increase trust in and awareness of clinical trials. Now, because of this relationship, we will be able to support even more
About Greater Gift (www.greatergift.org): Greater Gift is a non-profit organization, founded in 2010, with a mission to increase awareness of clinical research, especially among underrepresented communities, to improve global health. Greater Gift builds bridges with underrepresented communities to engage them in research, ensure equal representation in clinical research and to increase access to research as an option for medical care. Since its founding, Greater Gift has honored 130,000 clinical trial volunteers by making donations of vaccines and meals to children in need in their honor.
About AGTC: AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and
About: 2020 On-site: 2020 On-site has been revolutionizing how vision care benefits are being delivered to companies and patients for 7 years. Its state-of-the-art mobile vision clinics serve over 450 companies in the greater
Source: Applied Genetic Technologies Corporation